1) 请以中文翻译以下的文章:

If we are unable to hire qualified personnel and retain or motivate key personnel, we may not be able to grow effectively.

Our future success depends on our continuing ability to identify, hire, develop, motivate and retain skilled personnel for all areas of our organization. Competition in our industry for qualified employees is very competitive. Our continued ability to compete effectively depends on our ability to attract new employees and to retain and motivate our existing employees.

The economy of Malaysia in general might not grow as quickly as expected, which could adversely affect our revenues and business prospects.

Our business and prospects depend on the continuing development and expansion of the consulting industry in Malaysia, which in turn depends upon the continuing growth of the economy of Malaysia in general, as well as product and service providers. We cannot assure you, however, that the Malaysia consulting industry will continue to grow at the same pace as in the past.

2) 请以中文翻译以下的文章:

We plan on purchasing raw products from factories and wholesalers locally or from China. Once we have our raw product purchased or delivered we plan on getting them designed, manufactured and assembled locally. We currently do not have any contract or agreement in place with any factories and wholesalers locally or from China. We also do not have any contract or agreement in place with any designers, manufacturers, or assemblers who will complete and finalize our products before we can display them on our website to sell. We plan on contacting factories, wholesalers, designers, manufacturers and assemblers after completion of our offering if maximum number of shares are sold.

3) 请以英文翻译以下的文章:

公司计划在 2018 年在欧州,美国,加拿大和日本四个区域同时发表由医学会承认的学术论文(国际期刊)。这包含了临床效果,患者回馈,经济效益 3 个方面的评估,在欧美和其他一些国家被称为"医疗技术评估",该类评估目前正被各医疗机构广泛使用,用来提高医疗诊疗品质。学术发表费用每篇/区域平均 5,000,000 新台币,我们预算四个区域的论文发表费用约 50,000,000 新台币,并打算在首次公开募股(IPO)融得此经费。公司预计 2021 年净利润达到 9,000,000 美金,通过公司成立"不洗肾中心",并联打造养生村(慢性病调养中心),收购上下游公司,形成集肾病研究中心,健康管理,智能专家系统,生物科技,医疗器械,保健系列产品于一体的完整医疗产业链,并且符合所有美国纳斯达克资本市场(NASDAQ Capital Market)板块的条件,估计 2021 年转板后市值膨胀 10X 至 360,000,000 美元。